Company news
Allergy Therapeutics Plc (LSE:AGY) news
Allergy Therapeutics Plc news releases on 6ix. Latest, Sep 17, 2024: Progression of patient cohorts in PROTECT Trial
Press releases — page 2
Progression of patient cohorts in PROTECT Trial
September 17, 2024
Trading update for the year ended 30 June 2024
July 22, 2024
Appointment of Nominated Adviser and Sole Broker
July 22, 2024
Launch of new Company Long Term Incentive Plan
July 4, 2024
Appointment of Non-Executive Director
June 27, 2024
Successful meetings with Paul Ehrlich Institut
June 3, 2024
Further detail from G306 Phase III field trial
May 7, 2024
Director Resignation
April 3, 2024
Interim Results for six months ended 31 Dec 2023
March 27, 2024
VLP Peanut PROTECT Trial Update
March 12, 2024
Appointment of Shaun Furlong to Board of Directors
March 11, 2024
Result of AGM
March 8, 2024
Half-Year Trading Update 2024
February 14, 2024
Notice of 2023 Annual General Meeting
February 9, 2024
Allergy Therapeutics plc - Publication of Annual Report and Accounts 2023
January 31, 2024
Restoration - Allergy Therapeutics plc
January 30, 2024
Publication of Annual Report and Accounts 2023
January 30, 2024
Total Voting Rights
January 4, 2024
Suspension - Allergy Therapeutics plc
January 2, 2024
Amendment to existing Facility Agreement
December 27, 2023
Annual Report and Accounts Delayed
December 15, 2023
PDMR dealing and Total Voting Rights
December 13, 2023
G306 Phase III trial meets key endpoints
December 13, 2023
Holding(s) in Company
November 28, 2023
G306 Grass Phase III trial meets primary endpoint
November 14, 2023
Director/PCA Dealing
November 10, 2023
Offer Closure
November 10, 2023
Posting of Offer Document
October 19, 2023
Unconditional Mandatory Cash Offer
October 16, 2023
Result of Open Offer and Subscription
October 13, 2023
Publication of Open Offer Circular – Amendment
September 27, 2023
Publication of Open Offer Circular
September 27, 2023
Unaudited Preliminary Results 2023
September 27, 2023
Phase I VLP Peanut PROTECT trial progress
September 26, 2023
Satisfaction of FDI clearance conditions
September 22, 2023
Trading update for the year ended 30 June 2023
August 10, 2023
Result of General Meeting
July 31, 2023
Appointment of Chief Financial Officer
July 10, 2023
Allergy Therapeutics plc - Interim Results for the six months ended 31 December 2022 and Lifting of Suspension in Trading
June 20, 2023
Interim Results and Lifting Suspension in Trading
June 19, 2023
Publication of Annual Report and Accounts 2022
June 19, 2023
Allergy Therapeutics shares key findings at EAACI
June 9, 2023
Project Zebra Rule 2.9 Announcement
April 20, 2023
Skin-prick testing completes in PROTECT Trial
April 19, 2023
£40.75 million Facility with Equity Financing
April 6, 2023
Trading and Business Update
April 6, 2023
Publication of Interim Results Delayed
March 29, 2023
Patients dosed in VLP Peanut PROTECT trial
March 27, 2023
PDMR Dealing
March 3, 2023
Half-Year Trading Update 2023
January 20, 2023